Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone Outperforms VRd Alone for Multiple Myeloma - report from ASH2023

Professor Pieter Sonneveld explains that newly diagnosed patients with multiple myeloma who received daratumumab along with the standard care regimen of bortezomib, lenalidomide, and dexamethasone showed significantly higher rates of survival without disease progression compared with those who received VRd alone. Results from the phase III Perseus trial were reported at the 2023 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:daratumumab-plus-bortezomib-lenalidomide-and-dexamethasone-outperforms-vrd-alone-multiple-myeloma